The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping
The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Seocho-gu
-
Seoul, Seocho-gu, Korea, Republic of, 07651
- Seoul St.Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of stomach cancer
- ASA class I-III
- no metastatic disease
Exclusion Criteria:
- hepatic, renal disease
- chronic inflammatory disease, eg. rheumatoid arthritis
- steroid or anti-inflammatory drug medication
- allergies to study drugs
- neuropsychiatric disease
- refusal of participation
- breast feeding or pregnancy
- weight < 40 kg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: study group
The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.<120
mg/h).
|
The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
|
|
Placebo Comparator: control group
The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
|
The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum concentration of NET(neutrophil extracellular trapping)-related biomarker
Time Frame: 24 hours after surgery
|
NET-related biomarker (citrullinated histone3, neutrophil elastase, myeloperoxidase)
|
24 hours after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
quality of recovery
Time Frame: 24 hours after surgery
|
The quality of recovery is assessed using questionnaire.
This questionnaire includes 15 items.
The score range is from 0 to 150.
The higher score means the better quality of recovery after surgery.
|
24 hours after surgery
|
|
postoperative pain
Time Frame: 24 hours after surgery
|
The postoperative pain is assessed using numeric rating scale (NRS; 0=no pain, 10=the maximal pain)
|
24 hours after surgery
|
|
survival of patients
Time Frame: 5 years
|
The survival of patients is assessed using electronic medical record.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Young Eun Moon, MD, Seoul St. Mary's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- NET-lidocaine-stomach cancer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.